Bretaris® Genuair® (aclidinium bromide) is a new long-acting selective muscarinic receptor antagonist (LAMA) approved by the Therapeutic Goods Administration (TGA) as a long-term maintenance bronchodilator in adult patients with chronic obstructive pulmonary disease (COPD).

Aclidinium provides significant and sustained bronchodilation and improves COPD symptoms compared to placebo. Changes in forced expiratory volume (FEV1) are similar to those associated with tiotropium (Spiriva®), however one review noted that using the pre-loaded dry-powder inhaler, 400 micrograms twice a day, offers higher patient satisfaction, and fewer critical errors, compared to using a HandiHaler® once daily.

The March meeting of the Pharmaceutical Benefits Advisory Committee (PBAC) recommended aclidinium for inclusion as a restricted benefit on the Pharmaceutical Benefits Scheme (PBS). It is currently only available, at no charge, under a Bretaris® Genuair® Product Familiarisation Programme offered by A. Menarini Australia Pty Ltd.

Please review full product information before prescribing.

References:

  1. Beier J, Kirsten AM, Mróz R, Segarra R, Chuecos F, Caracta C, Gil EG.Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled Phase IIIb study. COPD. 2013 Aug; 10(4): 511-22.
  2. Bretaris® Genuair® (aclidinium bromide) Australian approved product information. Chatswood: A. Menarini Australia Pty Ltd. Approved 25 March 2014.
  3. Jones PW, Singh D, Bateman ED, Agusti A, Lamarca R, de Miquel G, et al. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study. Eur Respir J. 2012 Oct; 40(4): 830-6.
  4. Kerwin EM, D’Urzo AD, Gelb AF, Lakkis H, Garcia Gil E, Caracta CF; ACCORD I study investigators. Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD. 2012 Apr; 9(2): 90-101.
  5. Pharmaceutical Benefit Advisory Committee. March 2014 PBAC Meeting Outcomes – Positive Recommendations. Canberra: PBS; 2014.
  6. van der Palen J, Ginko T, Kroker A, van der Valk P, Goosens M, Padullés L, Seoane B, et al.Preference, satisfaction and errors with two dry powder inhalers in patients with COPD. Expert Opin Drug Deliv. 2013 Aug; 10(8): 1023-31.

Subscribe Knowledge Centre Updates

Enter your details to receive Knowledge Centre updates